Medication Adherence
Conditions
Brief summary
The current study will use the double-blind balanced placebo design to examine differences between expectancies versus the pharmacological effects of varenicline medication administered for two weeks to cigarette smokers. The double-blind balanced placebo design includes medication administration (active medication v. placebo) and medication information (told truth v. deception) resulting in four groups of smokers: (1) told therapeutic dose (TD) medication + received TD medication; (2) told TD medication + received placebo; (3) told low dose (LD) medication+ received TD dose medication; (4) told LD medication + received placebo. Ecological momentary assessments (EMA) in the form of Daily Dairies delivered via smartphone will assess real-time side effects, withdrawal symptoms, cigarettes smoked, medication use, and reasons for medication non-adherence.
Detailed description
The current proposal will utilize the double-blind balanced placebo design to differentiate expectancies versus pharmacologic mechanisms of varenicline administered to varenicline naïve smokers seeking treatment (N = 80) for two-weeks. Race block randomization (controlling for baseline expectancies) will be used to randomize participants. The double-blind balanced placebo design includes a cross-balanced medication administration (active medication v. placebo) and instructional set (told truth v. deception) resulting in four groups of smokers seeking treatment (n = 20 for each): (1) told therapeutic dose (TD) medication + received TD medication; (2) told TD medication + received placebo; (3) told low dose (LD) medication+ received TD dose medication; (4) told LD medication + received placebo. Participants will be told they received low dose (rather than placebo) due to concerns that participants will not take a medication that they believe to be a placebo. Ecological momentary assessments (EMA) in the form of Daily Dairies delivered via smartphone will assess real-time side effects, withdrawal symptoms, cigarettes smoked, medication use, and reasons for medication non-adherence. The current proposal will test the following specific aims: Specific Aim 1: Examine the main effects of instructional set and pharmacology. Hypothesis 1: Main effects for TD instructional set and active medication administration will result in reduced medication adherence compared with LD instructional set and placebo medication. Specific Aim 2: Examine the interaction between instructional set and pharmacology. Hypothesis 2: There will be a synergistic (i.e., non-additive) effect between instructional set and pharmacology. Specifically, those assigned to the TD instructional set and active medication group will result in a 50% discontinuation compared to a 20% discontinuation in the TD instructional set and placebo medication group. Exploratory Aim: Evaluate moderators of pharmacology and expectancy effects on medication adherence. First, we will conduct exploratory examination of baseline medication expectancies moderating the relationship between pharmacology and medication adherence. Second, we will conduct an exploratory evaluation of potential moderators (e.g., gender and race) of pharmacology and baseline medication expectancy.
Interventions
Participants will be provided varenicline medication
Participants will be provided placebo medication
Sponsors
Study design
Masking description
double-blind
Intervention model description
Balanced placebo design
Eligibility
Inclusion criteria
* 18 years or older * Smoking at least 5 cigarettes per day (cpd) for the past year * A carbon monoxide (CO) \>10ppm * English speaking * Must own a cellphone with SMS text capacity with Internet access OR daily use of email * Must be varenicline naïve * Express a desire to quit smoking
Exclusion criteria
* Living in a restricted environment (e.g., prison or jail facility, etc.) * Pregnant or nursing * Currently enrolled in a smoking cessation treatment program, using NRT products, or prescribed bupropion or varenicline * Known allergy to varenicline * History of kidney disease, dialysis or known kidney impairment * Cognitive impairment or unstable psychiatric condition that interferes with the informed consent process (individuals stable on psychiatric medications will be included) * Daily or exclusive use of other tobacco products * Current suicidal or homicidal ideation or a suicidal attempt within the past 12 months * History of stroke, heart attack, or seizures
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Medication Adherence | Days 1 - 13 | Self-reported medication adherence measured through a single item assessing medication compliance. The item is answered as yes (scored as 1) or no (scored as 0). This measure combines all responses from Day 1 through Day 13 of this study to provide a total measure of medication adherence ranging from 0% (missed all doses) to 100% (took every dose as prescribed). Higher scores indicate better outcomes (i.e., better adherence to medication). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Medication Expectancies | Baseline and Day 14 | Medication expectancies will be measured through the Beliefs and Attitudes about Varenicline (BAV) scale which is a 6-item questionnaire adapted to assess varenicline expectancies. This measure is rated on a scale from 1 (not at all) to 5 (extremely). The measure has a minimum score of 6 and a maximum score of 30. Higher scores indicating better outcomes (i.e., stronger positive beliefs about using varenicline). |
Other
| Measure | Time frame | Description |
|---|---|---|
| Side Effects | Day 14 | A 30-item self-report measure of the presence (or not) of symptoms commonly associated with varenicline side effects and nicotine withdrawal. Items are rated as No (scored as 0) or Yes (scored as 1). A total score was calculated to reflect the total number of reported side effects. This measure has a minimum score of 0 and a maximum score of 30. Higher scores indicate worse outcomes (i.e., greater frequency of experienced side effects). |
Countries
United States
Participant flow
Pre-assignment details
None, all participants that were enrolled in the study were randomized into one of the four conditions.
Participants by arm
| Arm | Count |
|---|---|
| Therapeutic Dose/Varenicline Participants were told they were provided with a therapeutic dose of varenicline and they received varenicline medication. | 20 |
| Therapeutic Dose/Placebo Participants were told they received a therapeutic dose varenicline, but they received a placebo. | 20 |
| Low Dose/Varenicline Participants were told they received a very low dose varenicline, but they received a therapeutic dose varenicline. | 20 |
| Low Dose/Placebo Participants were told they received a very low dose varenicline, but they received a placebo. | 20 |
| Total | 80 |
Baseline characteristics
| Characteristic | Therapeutic Dose/Varenicline | Total | Low Dose/Placebo | Low Dose/Varenicline | Therapeutic Dose/Placebo |
|---|---|---|---|---|---|
| Age, Continuous | 49.15 years STANDARD_DEVIATION 2.59 | 46.86 years STANDARD_DEVIATION 11.51 | 45.30 years STANDARD_DEVIATION 2.59 | 45.00 years STANDARD_DEVIATION 2.59 | 48.00 years STANDARD_DEVIATION 2.59 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 2 Participants | 1 Participants | 1 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 20 Participants | 78 Participants | 19 Participants | 19 Participants | 20 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 10 Participants | 40 Participants | 10 Participants | 10 Participants | 10 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 9 Participants | 39 Participants | 10 Participants | 10 Participants | 10 Participants |
| Sex: Female, Male Female | 5 Participants | 31 Participants | 13 Participants | 5 Participants | 8 Participants |
| Sex: Female, Male Male | 15 Participants | 49 Participants | 7 Participants | 15 Participants | 12 Participants |
| Stanford Expectations of Treatment Scale: Negative Subscale | 3.42 units on a scale STANDARD_DEVIATION 0.34 | 3.33 units on a scale STANDARD_DEVIATION 1.48 | 3.3 units on a scale STANDARD_DEVIATION 0.34 | 3.4 units on a scale STANDARD_DEVIATION 0.34 | 3.2 units on a scale STANDARD_DEVIATION 0.34 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 20 | 0 / 20 | 0 / 20 | 0 / 20 |
| other Total, other adverse events | 1 / 20 | 1 / 20 | 1 / 20 | 1 / 20 |
| serious Total, serious adverse events | 0 / 20 | 0 / 20 | 0 / 20 | 0 / 20 |
Outcome results
Medication Adherence
Self-reported medication adherence measured through a single item assessing medication compliance. The item is answered as yes (scored as 1) or no (scored as 0). This measure combines all responses from Day 1 through Day 13 of this study to provide a total measure of medication adherence ranging from 0% (missed all doses) to 100% (took every dose as prescribed). Higher scores indicate better outcomes (i.e., better adherence to medication).
Time frame: Days 1 - 13
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Therapeutic Dose/Varenicline | Medication Adherence | 85.36 Percentage |
| Therapeutic Dose/Placebo | Medication Adherence | 86.79 Percentage |
| Low Dose/Varenicline | Medication Adherence | 81.93 Percentage |
| Low Dose/Placebo | Medication Adherence | 86.09 Percentage |
Medication Expectancies
Medication expectancies will be measured through the Beliefs and Attitudes about Varenicline (BAV) scale which is a 6-item questionnaire adapted to assess varenicline expectancies. This measure is rated on a scale from 1 (not at all) to 5 (extremely). The measure has a minimum score of 6 and a maximum score of 30. Higher scores indicating better outcomes (i.e., stronger positive beliefs about using varenicline).
Time frame: Baseline and Day 14
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Therapeutic Dose/Varenicline | Medication Expectancies | 3.56 units on a scale |
| Therapeutic Dose/Placebo | Medication Expectancies | 3.65 units on a scale |
| Low Dose/Varenicline | Medication Expectancies | 3.50 units on a scale |
| Low Dose/Placebo | Medication Expectancies | 3.44 units on a scale |
Side Effects
A 30-item self-report measure of the presence (or not) of symptoms commonly associated with varenicline side effects and nicotine withdrawal. Items are rated as No (scored as 0) or Yes (scored as 1). A total score was calculated to reflect the total number of reported side effects. This measure has a minimum score of 0 and a maximum score of 30. Higher scores indicate worse outcomes (i.e., greater frequency of experienced side effects).
Time frame: Day 14
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Therapeutic Dose/Varenicline | Side Effects | 1.50 Symptoms | Standard Error 0.57 |
| Therapeutic Dose/Placebo | Side Effects | 3.40 Symptoms | Standard Error 0.54 |
| Low Dose/Varenicline | Side Effects | 2.00 Symptoms | Standard Error 0.61 |
| Low Dose/Placebo | Side Effects | 1.89 Symptoms | Standard Error 0.57 |